Dr Anne-Marie Martin, SVP Precision Medicine, R&D at GSK tells us how cutting-edge technologies are helping her team identify meaningful, predictive biomarkers, about the modalities she’s tracking and explains how these advances will impact patients.
Lead Editorial
